1‑calcium phosphate‑uracil, a synthesized pyrimidine derivative agent, has anti‑proliferative, pro‑apoptotic and anti‑invasion effects on multiple tumor cell lines

Peng,Jing; Chen,Xinlian; Hu,Qian; Yang,Mei; Liu,Hongqian; Wei,Wei; Liu,Shanling; Wang,He

doi:10.3892/mmr.2014.2489

1‑calcium phosphate‑uracil, a synthesized pyrimidine derivative agent, has anti‑proliferative, pro‑apoptotic and anti‑invasion effects on multiple tumor cell lines

Authors:
- Jing Peng
- Xinlian Chen
- Qian Hu
- Mei Yang
- Hongqian Liu
- Wei Wei
- Shanling Liu
- He Wang
View Affiliations

Affiliations: Laboratory of Genetics, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Laboratory of Cell and Gene Therapy, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: August 14, 2014 https://doi.org/10.3892/mmr.2014.2489
Pages: 2271-2278
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

1‑calcium phosphate‑uracil (1‑CP‑U), a synthetic pyrimidine derivative, has been documented to demonstrate a variety of different biological activities. However, the potency and mechanisms of this agent's anti-cancer activity have not been elucidated to date. In the present study, the anti‑cancer effects of 1‑CP‑U were examined in a range of in vitro assays. Different cell lines were treated with 1‑CP‑U at varied concentrations (0.7, 1.0, 1.4 µmol/l) for indicated durations. The cell proliferation was then examined by MTT assay. The cellular apoptotic effects were detected by Hoechst 33342 and Annexin V/propidium iodide staining, while the capacity of 1‑CP‑U on invasion and migration were examined by cell invasion and wound healing assays. The expression of matrix metalloproteinase proteins, as well as pro‑ and antiapoptotic proteins was detected by western blotting analysis. The results identified that 1‑CP‑U was able to inhibit the viability of SKOV3, HeLa, SMMC‑7721 and A549 cell lines in a dose‑ and time‑dependent manner, while it exerted only marginal toxic effects on non‑cancerous cells. The IC50 concentration of 1‑CP‑U for tumor cell lines was ~1.0 µmol/l. The growth inhibition induced by 1‑CP‑U was accompanied by a broad spectrum of pro‑apoptotic activities, in which different cell lines varied in their sensitivity to 1‑CP‑U. Meanwhile, the increased expression of the pro‑apoptotic protein B-cell lymphoma-2 (Bcl-2)-associated X and a marked reduction of Bcl‑2 levels were associated with increased 1‑CP‑U concentrations. Additionally, anti‑migration and anti‑invasion effects of 1‑CP‑U were evidently associated with the downregulation of matrix metalloproteinase proteins. Of note, it was observed that 1‑CP‑U signiﬁcantly inhibited both the migration and invasion at a lower concentration, as compared with the dose required to achieve signiﬁcant inhibition of apoptosis. These results indicated that 1‑CP‑U appeared to be a more effective inhibitor of cell migration and invasion, rather than of apoptosis. In conclusion, the present study was the first, to the best of our knowledge, to demonstrate the function of 1‑CP‑U in tumor proliferation, apoptosis and invasion with specific effects against cancer cells in vitro, suggesting 1‑CP‑U as a potential novel anticancer agent.

View Figures

View References

1	Eckhardt S: Recent progress in the development of anticancer agents. Curr Med Chem Anticancer Agents. 2:419–439. 2002. View Article : Google Scholar : PubMed/NCBI
2	Xu Y, Xin Y, Diao Y, Lu C, Fu J, Luo L and Yin Z: Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PLoS One. 6:e291692011. View Article : Google Scholar : PubMed/NCBI
3	Li J, Zhao YF, Zhao XL, Yuan XY and Gong P: Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines. Arch Pharm (Weinheim). 339:593–597. 2006.
4	Manetti F, Brullo C, Magnani M, Mosci F, Chelli B, Crespan E, Schenone S, Naldini A, Bruno O, Trincavelli ML, Maga G, Carraro F, Martini C, Bondavalli F and Botta M: Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 51:1252–1259. 2008.
5	Ning QZ: 1-Calcium phosphate-uracil and method for preparing thereof. US patent 20050277622. Filed June 10, 2004; Issued December 15, 2005.
6	Lowe SW, Cepero E and Evan G: Intrinsic tumour suppression. Nature. 432:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
7	Lowe SW and Lin AW: Apoptosis in cancer. Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar
8	Kim R, Emi M and Tanabe K: The role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol Ther. 5:1429–1442. 2006. View Article : Google Scholar : PubMed/NCBI
9	Hasenjager A, Gillissen B, Muller A, Normand G, Hemmati PG, Schuler M, Dorken B and Daniel PT: Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-xL in a strictly caspase-3-dependent manner in human carcinoma cells. Oncogene. 23:4523–4535. 2004. View Article : Google Scholar
10	Tang F, Zhang R, He Y, Zou M, Guo L and Xi T: MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. PLoS One. 7:e354352012. View Article : Google Scholar : PubMed/NCBI
11	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
12	Geng W, Ng KT, Sun CK, Yau WL, Liu XB, Cheng Q, Poon RT, Lo CM, Man K and Fan ST: The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma. PLoS One. 6:e273622011. View Article : Google Scholar : PubMed/NCBI
13	Wang L, Kuang L, Pan X, Liu J, Wang Q, Du B, Li D, Luo J, Liu M, Hou A and Qian M: Isoalvaxanthone inhibits colon cancer cell proliferation, migration and invasion through inactivating Rac1 and AP-1. Int J Cancer. 127:1220–1229. 2010. View Article : Google Scholar : PubMed/NCBI
14	Amr AG, Mohamed AM, Mohamed SF, Abdel-Hafez NA and Hammam Ael-F: Anticancer activities of some newly synthesized pyridine, pyrane, and pyrimidine derivatives. Bioorg Med Chem. 14:5481–5488. 2006. View Article : Google Scholar : PubMed/NCBI
15	Moriarty KJ, Koblish HK, Garrabrant T, Maisuria J, Khalil E, Ali F, Petrounia IP, Crysler CS, Maroney AC, Johnson DL and Galemmo RA Jr: The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors. Bioorg Med Chem Lett. 16:5778–5783. 2006.PubMed/NCBI
16	Maquoi E, Sounni NE, Devy L, Olivier F, Frankenne F, Krell HW, Grams F, Foidart JM and Noël A: Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res. 10:4038–4047. 2004. View Article : Google Scholar
17	Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 292:727–730. 2001. View Article : Google Scholar : PubMed/NCBI
18	Verrier F, Deniaud A, Lebras M, Métivier D, Kroemer G, Mignotte B, Jan G and Brenner C: Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis. Oncogene. 23:8049–8064. 2004. View Article : Google Scholar
19	Kim YM, Kim IH and Nam TJ: Inhibition of AGS human gastric cancer cell invasion and proliferation by Capsosiphon fulvescens glycoprotein. Mol Med Rep. 8:11–16. 2013.PubMed/NCBI
20	Gross J and Lapiere CM: Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA. 48:1014–1022. 1962. View Article : Google Scholar
21	Singh RP, Raina K, Sharma G and Agarwal R: Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res. 14:7773–7780. 2008. View Article : Google Scholar
22	Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA and Stetler-Stevenson WG: Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res. 51:439–444. 1991.PubMed/NCBI
23	Dashevsky O, Varon D and Brill A: Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer. 124:1773–1777. 2009. View Article : Google Scholar : PubMed/NCBI
24	Kitamura T and Taketo MM: Keeping out the bad guys: gateway to cellular target therapy. Cancer Res. 67:10099–10102. 2007. View Article : Google Scholar : PubMed/NCBI
25	Björklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
26	Langenskiöld M, Holmdahl L, Falk P and Ivarsson ML: Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis. 20:245–252. 2005.PubMed/NCBI
27	Nakamura ES, Koizumi K, Kobayashi M and Saiki I: Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. Cancer Sci. 95:25–31. 2004. View Article : Google Scholar